Pay-for-Performance in the US: What Could Work, What Won't
In theory, pay-for-performance (P4P) contracts could be highly desirable tools to address shifting dynamics of the pharma market, but, in practice, they’re likely to remain rare because they’re expensive and complicated to implement. Two recent, high-profile collaborations between
pharma companies and payors in the US highlight growing interest in P4P arrangements, but experts are divided over whether they can be widely emulated.
By Wendy Diller
Performance-based contracting between payors and pharma, both in the US and Europe, is capturing the attention of a health care community looking for new ways of doing business in an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
